Skip to content
Therapy But Better – Lifestyle
Author:
Eton Pharmaceuticals
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
November 6, 2026
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
November 5, 2026
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
November 4, 2026
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
November 2, 2026
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
October 29, 2026
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
September 28, 2026
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
August 27, 2026
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 13, 2026
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
August 5, 2026
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
August 3, 2026
1
2
Next Page
→